在花费了一年时间设计整个基金会系统的数据集结构之后,DeepMind开发了一个软件界面,可用于监测多种病情,并为开放创新的生态系统提供一个平台。
Open, that is, except that the platform is strictly owned and controlled by DeepMind under a time-bound licence that prevents the Royal Free hospital working directly with any other provider.
不过,这种开放是有限度的——整个平台由DeepMind根据一项有时间限制的许可协议(阻止皇家自由医院与其他任何提供商直接合作)严格拥有和掌控。
DeepMind, for its part, wishes to enable a community of innovators to develop niche applications over the top of data acquired through the first deal.
DeepMind希望借此形成一个创新者社区,在通过第一项交易获得的数据基础上开发细分应用。
Many of DeepMind’s aspirations are laudable, particularly its promises to bring cutting-edge provenance, transparency and audit to data flows.
DeepMind有不少值得赞许的抱负,特别是该公司承诺将把尖端的来源鉴定、透明化以及审计技术应用到数据流上。
However, it is critical that this company’s dealmaking does not involve special treatment, particularly given it can only do much of what it does because of the money and power of Google, its patron, which has long coveted the healthcare market.
【谷歌医疗数据交易引发质疑】相关文章:
★ 美国大选相关资讯
最新
2019-01-07
2019-01-07
2019-01-07
2019-01-07
2019-01-07
2019-01-05